ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1845

Development of a Scoring System for Accurate Lupus Nephritis Case Identification in Real-World Databases
Abstract Number: 1093

Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases
Abstract Number: 0847

Development of an IFN 5-Gene Signature Score to Identify IFN-high and IFN-low Subsets and as a Pharmacodynamic Biomarker for Deucravacitinib Treatment in a Phase 2 Trial in Patients with Systemic Lupus Erythematosus
Abstract Number: 2022

Development of an mHealth App for Lupus: Insights from a Human-Centered Design Approach
Abstract Number: 2018

Development of an Osteoporosis Treatment Gap Dashboard
Abstract Number: 0559

Development of Charlson Comorbidity Index (CCI) Comorbidities and CCI Score in Danish Nationwide Cohort of 3,178 Patients with Newly Diagnosed Systemic Lupus Erythematosus
Abstract Number: 0549

Development of Customized Digital Cognitive Assessment Battery: A Pilot Use Case in SLE Patients
Abstract Number: 2444

Development of Engineered Smith-Specific Regulatory T Cells to Treat Lupus Nephritis
Abstract Number: 0949

Development of Interstitial Pneumonia with Autoimmune Features in Conditional Tgfb3 Deletion
Abstract Number: 1558

Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement
Abstract Number: 2184

Development of Salivary Gland Organoids to Study Sjögren Syndrome
Abstract Number: 1910

Development of the American College of Rheumatology Toolkit for Implementation of Rheumatoid Arthritis Outcome Measures in Clinical Practice
Abstract Number: 1368

Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s
Abstract Number: 2522

Diabetes Mellitus Impacts Primary Total Hip Arthroplasty Outcomes: A National Cohort Study
Abstract Number: 2101

Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].